Palliative Management of Pancreatic Cancer
Author:
Dev Rony,Javle Milind
Publisher
Springer New York
Reference79 articles.
1. Merchant N, Berlin J. Past and future of pancreas cancer: are we ready to move forward together? J Clin Oncol. 2008;26(21):3478–80.
2. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.
3. Bernhard J, Dietrich D, Scheithauer W, et al. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial – SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol. 2008;26(22):3695–701.
4. Bernhard J, Dietrich D, Scheithauer W, et al. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial – SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol. 2008;26(22):3695–701.
5. Reyes-Gibby CC, Chan W, Abbruzzese JL, et al. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. J Pain Symptom Manag. 2007;34(3):244–52.